非小细胞肺癌患者驱动基因状态与静脉血栓栓塞症的相关研究
Relationship between Driver Gene Status and Venous Thromboembolism in Patients with Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2023.13112571, PDF,   
作者: 樊敏捷：吉首大学医学院，湖南 吉首；湘西自治州人民医院，湖南 吉首；徐朝久*：湘西自治州人民医院，湖南 吉首；秧茂盛：吉首大学医学院，湖南 吉首
关键词: 非小细胞肺癌；驱动基因状态；静脉血栓；Non-Small Cell Lung Cancer； Gene Mutation Status； Venous Thromboembolism
摘要: 恶性肿瘤和临床血栓形成之间的联系已经被认识数年了。在大部分病例中，患者并非死于癌症，而是死于治疗相关并发症。癌症本身是癌症患者最常见的死亡原因，血栓形成仅次于癌症本身。目前，对影响非小细胞肺癌(NSCLC)患者静脉血栓栓塞发生的风险因素进行了大量研究。近年来，一些相关的文献报道，常见的驱动基因突变(EGFR, ALK, ROS1, KRAS等)是影响VTE的共同因素，探讨这些共同因素对VTE发病的影响，为VTE的筛查提供了新的思路。现就NSCLC病人中的驱动基因状况与其发生发展的关系进行综述。
Abstract: The link between malignant tumors and clinical thrombosis has been known for years. In most cas-es, patients die not from cancer but from treatment-related complications. Cancer itself is the most common cause of death for cancer patients, and thrombosis is just that. Risk factors for venous thromboembolism (VTE) in patients with non-small cell lung cancer (NSCLC) have been extensively studied. In recent years, common driver mutations (EGFR, ALK, ROS1, KRAS, etc.) have been re-ported to be common factors affecting VTE. Exploring the impact of these common factors on VTE pathogenesis provides new insights for VTE screening. The relationship between driver gene status and progression in NSCLC patients is reviewed.
文章引用：樊敏捷, 徐朝久, 秧茂盛. 非小细胞肺癌患者驱动基因状态与静脉血栓栓塞症的相关研究[J]. 临床医学进展, 2023, 13(11): 18313-18319. https://doi.org/10.12677/ACM.2023.13112571

参考文献

[1] Xiong, W., Du, H., Ding, W., et al. (2020) The Association between Pulmonary Embolism and the Cancer-Related Genomic Altera-tions in Patients with NSCLC. Respiratory Research, 21, Article No. 185. [Google Scholar] [CrossRef] [PubMed]
[2] Kacimi, S., Moeinafshar, A., Haghighi, S.S., et al. (2022) Venous Thrombo-embolism in Cancer and Cancer Immunotherapy. Critical Reviews in Oncology/Hematology, 178, Article ID: 103782. [Google Scholar] [CrossRef] [PubMed]
[3] 马玉媛, 肖海娟, 杨林, 等. 肿瘤静脉血栓栓塞症的危险因素研究进展[J]. 医学研究杂志, 2022: 1-6.
[4] Qian, X., Fu, M., Zheng, J., et al. (2021) Driver Genes Associated with the Incidence of Ve-nous Thromboembolism in Patients with Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncol-ogy, 11, Article ID: 680191. [Google Scholar] [CrossRef] [PubMed]
[5] Van Dreden, P., Epsilonlalamy, I. and Gerotziafas, G.T. (2017) The Role of Tissue Factor in Cancer-Related Hypercoagulability, Tumor Growth, Angiogenesis and Metastasis and Future Therapeutic Strategies. Critical Reviews in Oncogenesis, 22, 219-248. [Google Scholar] [CrossRef] 
[6] Unruh, D. and Horbinski, C. (2020) Beyond Thrombosis: The Impact of Tissue Factor Signaling in Cancer. Journal of Hematology & Oncology, 13, Article No. 93. [Google Scholar] [CrossRef] [PubMed]
[7] Corrales-Rodriguez, L., Soulieres, D., Weng, X., et al. (2014) Mutations in NSCLC and Their Link with Lung Cancer-Associated Thrombosis: A Case-Control Study. Thrombosis Research, 133, 48-51. [Google Scholar] [CrossRef] [PubMed]
[8] Wang, J., Hu, B., Li, T., et al. (2019) The EGFR-Rearranged Adenocarci-noma Is Associated with a High Rate of Venous Thromboembolism. Annals of Translational Medicine, 7, 724. [Google Scholar] [CrossRef] [PubMed]
[9] Ades, S., Kumar, S., Alam, M., et al. (2015) Tumor Oncogene (KRAS) Status and Risk of Venous Thrombosis in Patients with Metastatic Colorectal Cancer. Journal of Thrombosis and Haemostasis, 13, 998-1003. [Google Scholar] [CrossRef] [PubMed]
[10] Dou, F., Zhang, Y., Yi, J., et al. (2020) Association of ALK Rearrangement and Risk of Venous Thromboembolism in Patients with Non-Small Cell Lung Cancer: A Prospective Cohort Study. Thrombosis Research, 186, 36-41. [Google Scholar] [CrossRef] [PubMed]
[11] Kaye, B., Ali, A., Correa, B.S.R., et al. (2023) The Role of EGFR Amplifi-cation in Deep Venous Thrombosis Occurrence in IDH Wild-Type Glioblastoma. Current Oncology, 30, 4946-4956. [Google Scholar] [CrossRef] [PubMed]
[12] Sussman, T.A., Abazeed, M.E., McCrae, K.R., et al. (2020) RNA Expression and Risk of Venous Thromboembolism in Lung Cancer. Research and Practice in Thrombosis and Haemostasis, 4, 117-123. [Google Scholar] [CrossRef] [PubMed]
[13] Yang, S., Yang, L., Wu, Y., et al. (2020) Anaplastic Lymphoma Kinase Rearrangement May Increase the Incidence of Venous Thromboembolism by Increasing Tissue Factor Expression in Advanced Lung Adenocarcinoma. Annals of Translational Medicine, 8, 1307. [Google Scholar] [CrossRef] [PubMed]
[14] Zhu, V.W., Zhao, J.J., Gao, Y., et al. (2021) Thromboembolism in ALK+ and ROS1+ NSCLC Patients: A Systematic Review and Meta-Analysis. Lung Cancer, 157, 147-155. [Google Scholar] [CrossRef] [PubMed]
[15] Roopkumar, J., Poudel, S.K., Gervaso, L., et al. (2021) Risk of Thromboembolism in Patients with ALK- and EGFR-Mutant Lung Cancer: A Cohort Study. Journal of Thrombosis and Haemostasis, 19, 822-829. [Google Scholar] [CrossRef] [PubMed]
[16] Al-Samkari, H., Leiva, O., Dagogo-Jack, I., et al. (2020) Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. Journal of Thoracic Oncology, 15, 1497-1506. [Google Scholar] [CrossRef] [PubMed]
[17] Ng, T.L., Smith, D.E., Mushtaq, R., et al. (2019) ROS1 Gene Rearrangements Are Associated with an Elevated Risk of Peridiagnosis Thromboembolic Events. Journal of Thoracic Oncology, 14, 596-605. [Google Scholar] [CrossRef] [PubMed]
[18] Chiari, R., Ricciuti, B., Landi, L., et al. (2020) ROS1-Rearranged Non-Small-Cell Lung Cancer Is Associated with a High Rate of Venous Thromboembolism: Analysis from a Phase II, Prospective, Multicenter, Two-Arms Trial (METROS). Clinical Lung Cancer, 21, 15-20. [Google Scholar] [CrossRef] [PubMed]
[19] Yi, J., Chen, H., Li, J., et al. (2022) The Association between ROS1 Rearrangement and Risk of Thromboembolic Events in Patients with Advanced Non-Small Cell Lung Cancer: A Multicenter Study in China. Thrombosis Journal, 20, Article No. 56. [Google Scholar] [CrossRef] [PubMed]
[20] Alexander, M., Pavlakis, N., John, T., et al. (2020) A Multicenter Study of Thromboembolic Events among Patients Diagnosed with ROS1-Rearranged Non-Small Cell Lung Cancer. Lung Cancer, 142, 34-40. [Google Scholar] [CrossRef] [PubMed]
[21] Zer, A., Moskovitz, M., Hwang, D.M., et al. (2017) ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated with a High Rate of Venous Thromboembolism. Clinical Lung Cancer, 18, 156-161. [Google Scholar] [CrossRef] [PubMed]

为你推荐